HylaPharm

Executive Summary

HylaPharm is a San Diego-based university spinout focused on reversing tumor-induced immune suppression to convert immunologically 'cold' tumors into 'hot' ones, thereby enhancing the efficacy of checkpoint inhibitors. The company's preclinical platform has demonstrated promising immune responses in canine cancer patients, offering a compelling translational bridge to human trials. By targeting the underlying mechanisms of immune evasion, HylaPharm aims to address the significant unmet need in the majority of cancer patients who do not respond to current immunotherapies. The approach has the potential to expand the reach of checkpoint inhibitors, reducing severe side effects by making treatment more targeted and effective. With a strong scientific foundation and positive proof-of-concept in a relevant large-animal model, HylaPharm is positioned as an early-stage innovator in immuno-oncology. The company's strategy leverages the naturally occurring immune suppression in tumors, providing a rationale for broad applicability across multiple cancer types. As it progresses toward human clinical trials, HylaPharm represents a promising opportunity for investors seeking exposure to novel cancer immunotherapy mechanisms.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Candidate70% success
• Q2 2026Publication of Canine Study Results in Peer-Reviewed Journal80% success
• Q4 2026Series A Funding Round60% success